ClinicalTrials.gg
TerminatedNCT06397768CORALUpdated Oct 5, 2026

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

A Phase 3 interventional study of RSVt vaccine and Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine in RSV Immunization, sponsored by Sanofi Pasteur, a Sanofi Company. Terminated at 72 sites in 3 countries. Open to participants aged 6 Months to 12 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention

How we know

Why this study was terminated
Sponsor decision

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,226
Allocation
Randomized
Ages
6 Months to 12 Months
Sex
All
01

Study summary

This study is a Phase III, randomized, single-blind, placebo-controlled, multi-center study to be conducted in healthy infants and toddlers which will be enrolled at approximately 6 months of age (Cohort 1) and approximately 12 months of age (Cohort 2). The primary objective of the study will be to assess non-inferiority of the RSV infant and toddler (RSVt) vaccine antibody response when administered concomitantly with routine pediatric vaccines at 6 months of age (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine [Vaxelis® or Pentacel® and Recombivax HB®] Prevnar 20®, and RotaTeq®), and 12 months of age (M-M-R II, VARIVAX, and Prevnar 20 or per local country recommendations) compared to when administered non-concomitantly.

Read the detailed description

The study duration is approximately 9 months for each participant.

  • Cohort 1: Visits at 6, 7, and 8 and 9 months of age for both groups with visit at 10 months of age for Group 2 only
  • Cohort 2: Visits at 12, 13, 14 and 15 months of age for both groups with visit at 16 months of age for Group 4 only
  • Routine pediatric vaccines (authorized auxiliary medicinal products (AxMP) will be administered at 6 months in Cohort 1 and 12 months of age in Cohort 2, as per Advisory Committee on Immunization Practice (ACIP) or local country recommendations.
02

Conditions studied

  • RSV Immunization
03

In context

Lead sponsor

Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.

Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.

First submitted after Sanofi Pasteur became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 12 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 6 months for Cohort 1 and 12 months for Cohort 2 on the day of inclusion ("6 months" means from the day of the 6-month birthday to the day before the 7-month birthday and "12 months" means from the day of the 12-month birthday to the day before the 13-month birthday)
  • Participants who are healthy as determined by medical evaluation including medical history and physical examination
  • For Cohort 1: Infant received doses of vaccines containing , diphtheria, tetanus, pertussis, Haemophilus influenzae type B (Hib), and inactivated poliovirus vaccine (IPV) antigens, with Advisory Committee on Immunization Practice (ACIP) recommended vaccines. The last dose(s) of these vaccines must be at least 28 days before the first study visit
  • Infant received the recommended doses of a recommended pneumococcal conjugate vaccine (as per local schedule) at least 28 days before the first study visit.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Known previous infection with diphtheria, tetanus, Hib, measles, mumps, rubella, rotavirus, pneumococcus, polio, virus
  • Known systemic to any of the study intervention components, or history of a life-threatening reaction to the study intervention used in the study or to a product containing any of the same substances
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • History of medically diagnosed wheezing
  • Any acute febrile illness in the past 48 hours that according to investigator judgment is significant enough to interfere with successful inoculation on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Probable or confirmed ongoing case of viral respiratory infection (including COVID 19, influenza, rhinovirus, etc.) at the time of enrollment. A prospective participant should not be included in the study until the respiratory infection has resolved.
  • Member of a household that contains an immunocompromised individual, including, but not limited to:
  • A person living with (HIV)
  • A person who has received chemotherapy within the 12 months prior to study enrollment
  • A person who has received (within the past 6 months) or is receiving (at the time of enrollment) immunosuppressant agents
  • A person living with a solid organ or bone marrow transplant
  • Potential close contact with other immunocompromised individual within 30 days after each vaccination as per investigator's discretion
  • History of definitive to any of the concomitant vaccines that will be administered as part of the study protocol
  • Participant's biological mother with previous receipt or planned administration of an RSV vaccine during pregnancy and/or breastfeeding
  • Receipt of any vaccine in the 4 weeks preceding RSVt vaccine administration or planned receipt of any vaccine outside of study protocol in the 4 weeks following RSVt vaccine administration, except for influenza and/or COVID-19 vaccination, which may be received at least 1 week before or 1 week after RSVt vaccine administration
  • Previous receipt of an investigational RSV vaccine or receiving any anti RSV product (such as ribavirin or RSV immune globulin) at the time of enrollment
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Receipt of intranasal and intra-ocular medications within 3 days prior to study enrollment
  • Previous receipt of an RSV monoclonal antibody within 6 months prior to the first study vaccine administration or planned receipt for duration of the study
  • For Cohort 1: Prior receipt of routine 6-month pediatric vaccine doses (as per local schedule)
  • For Cohort 2: Prior receipt of routine 12-month pediatric vaccine doses (as per local schedule)
  • Participation at the time of study enrollment (or in the 6 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure

Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
2,226 participants (actual)

Study arms

  • Experimental
    Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months)

    Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 6 months. Vaccines administered at age 6 months: RSVt Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered non-concomitantly at 7 months of age

    Biological: RSVt vaccine · Biological: Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine · Biological: Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine · Biological: Hepatitis B vaccine · Biological: Streptococcus pneumoniae vaccine · Biological: Rotavirus vaccine · Biological: Placebo

  • Experimental
    Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months)

    Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 7 months. Vaccines administered at age 6 months: Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered concomitantly at 6 months of age

    Biological: RSVt vaccine · Biological: Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine · Biological: Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine · Biological: Hepatitis B vaccine · Biological: Streptococcus pneumoniae vaccine · Biological: Rotavirus vaccine · Biological: Placebo

  • Experimental
    Cohort 2: Group 3- (RSVt vaccine concomitantly at 12 months)

    Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 12 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered non-concomitantly at 13 months of age

    Biological: RSVt vaccine · Biological: Streptococcus pneumoniae vaccine · Biological: Measles, mumps, and rubella vaccine · Biological: Varicella virus vaccine · Biological: Placebo

  • Experimental
    Cohort 2: Group 4- (RSVt vaccine non-concomitantly at 13 months)

    Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 13 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered concomitantly at 12 months of age

    Biological: RSVt vaccine · Biological: Streptococcus pneumoniae vaccine · Biological: Measles, mumps, and rubella vaccine · Biological: Varicella virus vaccine · Biological: Placebo

Interventions

  • BiologicalRSVt vaccine

    Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

    Also known as: 534

  • BiologicalDiphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine

    Drug page: VaxelisStudies of VaxelisVaxelis pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

    Also known as: Vaxelis®

  • BiologicalDiphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine

    Drug page: PentacelStudies of PentacelPentacel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

    Also known as: Pentacel®

  • BiologicalHepatitis B vaccine

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

    Also known as: RECOMBIVAX HB® or alternate monovalent hepatitis B vaccine

  • BiologicalStreptococcus pneumoniae vaccine

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

    Also known as: PREVNAR 20®

  • BiologicalRotavirus vaccine

    Pharmaceutical form:Oral solution-Route of administration:Oral

    Also known as: RotaTeq®

  • BiologicalMeasles, mumps, and rubella vaccine

    Drug page: Measles-Mumps-Rubella VaccineStudies of Measles-Mumps-Rubella VaccineMeasles-Mumps-Rubella Vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pharmaceutical form:Lyophilized live virus for reconstitution -Route of administration:Subcutaneous or Intramuscular

    Also known as: M-M-R® II

  • BiologicalChickenpox VaccineStudies of Chickenpox VaccineChickenpox Vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pharmaceutical form:Suspension for injection-Route of administration:Subcutaneous or Intramuscular

    Also known as: VARIVAX®

  • BiologicalPlacebo

    Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

06

What researchers measure

Primary outcomes

  1. RSV A serum neutralizing antibody titers at 28 days post dose 2 (D85) Groups 1 and 3

    Antibody titers at Day 85

    Time frame: Day 85

  2. RSV B serum neutralizing antibody titers at 28 days post dose 2 (D85) Groups 1 and 3

    Antibody titers at Day 85

    Time frame: Day 85

  3. RSV A serum neutralizing antibody titers at Day 113 Groups 2 and 4

    Antibody titers at Day 113

    Time frame: Day 113

  4. RSV B serum neutralizing antibody titers at Day 113 Groups 2 and 4

    Antibody titers at Day 113

    Time frame: Day 113

Secondary outcomes

  1. Anti- hepatitis B surface antigen (HBsAg) Immunoglobulin g (IgG) antibody (A)b concentrations ≥ 10 milli international units per milliliter (mIU/mL) Cohort 1

    Antibody titers 28 days after the 6 month routine vaccinations

    Time frame: 28 days after the 6 month routine vaccinations

  2. Anti- polyribosylribitol phosphate (PRP) Ab concentrations ≥ 0.15 micrograms per milliliter (µg/mL) Cohort 1

    Antibody titers 28 days after the 6 month routine vaccinations

    Time frame: 28 days after the 6 month routine vaccinations

  3. Anti-poliovirus types (1, 2, and 3) Ab titers ≥ 1:8 Cohort 1

    Antibody titers 28 days after the 6 month routine vaccinations

    Time frame: 28 days after the 6 month routine vaccinations

  4. Anti-pertussis Ab concentrations pertussis toxin, filamentous hemagglutinin , pertactin, fimbriae (PT, FHA, PRN, FIM) Cohort 1

    Antibody titers 28 days after the 6 month routine vaccinations

    Time frame: 28 days after the 6 month routine vaccinations

  5. Anti-diphtheria Ab concentrations ≥ 0.1 IU/mL Cohort 1

    Antibody titers 28 days after the 6 month routine vaccinations

    Time frame: 28 days after the 6 month routine vaccinations

  6. Anti-tetanus Ab concentrations ≥ 0.1 IU/mL Cohort 1

    Antibody titers 28 days after the 6 month routine vaccinations

    Time frame: 28 days after the 6 month routine vaccinations

  7. Anti-pneumococcal Ab concentrations measured by electrochemiluminescence (ECL) for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F Cohort 1

    Antibody titers 28 days after the 6 month routine vaccinations

    Time frame: 28 days after the 6 month routine vaccinations

  8. Anti-measles Ab concentrations ≥ 255 mIU/mL Cohort 2

    Antibody titers 28 days after the 12 month routine vaccinations

    Time frame: 28 days after the 12 month routine vaccinations

  9. Anti-mumps Ab concentrations ≥ 10 antibody units (AbU/mL) Cohort 2

    Antibody titers 28 days after the 12 month routine vaccinations

    Time frame: 28 days after the 12 month routine vaccinations

  10. Anti-rubella Ab concentrations ≥ 10 IU/mL Cohort 2

    Antibody titers 28 days after the 12 month routine vaccinations

    Time frame: 28 days after the 12 month routine vaccinations

  11. Anti-varicella Ab concentrations ≥ 5 glycoprotein enzyme-linked immunosorbent assay (gpELISA) units/mL Cohort 2

    Antibody 28 days after the 12 month routine vaccinations

    Time frame: 28 days after the 12 month routine vaccinations

  12. Anti-pneumococcal Ab concentrations measured by ECL Cohort 2

    Antibody titers 28 days after the 12 month routine vaccinations

    Time frame: 28 days after the 12 month routine vaccinations

  13. Descriptive: Anti-PRP Ab concentrations (µg/mL) Cohort 1

    Antibody titers 28 days after the 6 month routine vaccinations

    Time frame: 28 days after the 6 month routine vaccinations

  14. Descriptive: Anti-diphtheria Ab concentrations (IU/mL) Cohort 1

    Antibody titers 28 days after the 6 month routine vaccinations

    Time frame: 28 days after the 6 month routine vaccinations

  15. Descriptive: Anti-diphtheria Ab concentrations ≥ 0.01 IU/mL Cohort 1

    Antibody titers 28 days after the 6 month routine vaccinations

    Time frame: 28 days after the 6 month routine vaccinations

  16. Descriptive: Anti-tetanus Ab concentrations (IU/mL) Cohort 1

    Antibody titers 28 days after the 6 month routine vaccinations

    Time frame: 28 days after the 6 month routine vaccinations

  17. Descriptive: Anti-tetanus Ab concentrations ≥ 0.01 IU/mL Cohort 1

    Antibody titers 28 days after the 6 month routine vaccinations

    Time frame: 28 days after the 6 month routine vaccinations

  18. Descriptive: Anti-HBsAg Ab concentrations (mIU/mL) Cohort 1

    Antibody titers 28 days after the 6 month routine vaccinations

    Time frame: 28 days after the 6 month routine vaccinations

  19. Descriptive: Anti-HBsAg Ab concentrations ≥ 100 mIU/mL Cohort 1

    Antibody titers 28 days after the 6 month routine vaccinations

    Time frame: 28 days after the 6 month routine vaccinations

  20. Descriptive: Anti-poliovirus types (1, 2, and 3) Ab titers Cohort 1

    Antibody titers 28 days after the 6 month routine vaccinations

    Time frame: 28 days after the 6 month routine vaccinations

  21. Descriptive: Anti-measles Ab concentrations (mIU/mL) Cohort 2

    Antibody titers 28 days after the 12 month routine vaccinations

    Time frame: 28 days after the 12 month routine vaccinations

  22. Descriptive: Anti-mumps Ab concentrations (AbU/mL) Cohort 2

    Antibody titers 28 days after the 12 month routine vaccinations

    Time frame: 28 days after the 12 month routine vaccinations

  23. Descriptive: Anti-rubella Ab concentrations (IU/mL) Cohort 2

    Antibody titers 28 days after the 12 month routine vaccinations

    Time frame: 28 days after the 12 month routine vaccinations

  24. Descriptive: Anti-varicella Ab concentrations (gpELISA units/mL)

    Antibody titers 28 days after the 12 month routine vaccinations

    Time frame: 28 days after the 12 month routine vaccinations

  25. RSV A serum neutralizing antibody titers by baseline serostatus at Day 1 Cohort 1 and Cohort 2

    Antibody titers at Day 1

    Time frame: Day 1

  26. RSV B serum neutralizing antibody titers by baseline serostatus at Day 1 Cohort 1 and Cohort 2

    Antibody titers at Day 1

    Time frame: Day 1

  27. RSV A serum neutralizing antibody titers by baseline serostatus 28 days post-dose 2 1 Cohort 1 and Cohort 2

    Antibody titers 28 days post-dose 2

    Time frame: 28 days post-dose 2

  28. RSV B serum neutralizing antibody titers by baseline serostatus 28 days post-dose 2 Cohort 1 and Cohort 2

    Antibody titers 28 days post-dose 2

    Time frame: 28 days post-dose 2

  29. Presence of solicited administration site reactions within 21 days after each investigational medicinal product (IMP) administration Cohort 1 and Cohort 2

    Number of participants experiencing solicited administration site reactions

    Time frame: 21 days after each IMP administration

  30. Presence of solicited systemic reactions within 21 days after each IMP administration Cohort 1 and Cohort 2

    Number of participants experiencing solicited systemic site reactions

    Time frame: 21 days after each IMP administration

  31. Presence of unsolicited systemic adverse events (AEs) reported in the 30 minutes after each study intervention administration Cohort 1 and Cohort 2

    Number of participants experiencing unsolicited systemic adverse events

    Time frame: Within 30 minutes after each study intervention administration

  32. Presence of unsolicited AEs within 28 days after each study intervention administration Cohort 1 and Cohort 2

    Number of participants experiencing unsolicited AEs

    Time frame: Within 28 days after each study intervention administration

  33. Presence of medically attended adverse events (MAAEs) throughout the study Cohort 1 and Cohort 2

    Number of participants experiencing MAAEs

    Time frame: Throughout the study, approximately 9 months

  34. Presence of serious adverse events (SAEs) throughout the study Cohort 1 and Cohort 2

    Number of participants experiencing SAEs

    Time frame: Throughout the study, approximately 9 months

  35. Presence of adverse events of special interest (AESIs) throughout the study Cohort 1 and Cohort 2

    Number of participants experiencing AESIs

    Time frame: Throughout the study, approximately 9 months

07

Study locations

72 sites
  • Alabama Clinical Therapeutics - Birmingham - St. Vincent's Drive- Site Number : 8400007
    Birmingham, Alabama 35205, United States
  • South Alabama Medical Clinic- Site Number : 8400065
    Grand Bay, Alabama 36541, United States
  • MedPharmics - Mobile - Dauphin Street- Site Number : 8400017
    Mobile, Alabama 36608, United States
  • Northwest Arkansas Pediatric Clinic- Site Number : 8400002
    Fayetteville, Arkansas 72703, United States
  • Alliance Research Institute - Bell Gardens - Garfield Avenue- Site Number : 8400040
    Bell Gardens, California 90201, United States
  • Matrix Clinical Research - Huntington Park- Site Number : 8400018
    Huntington Park, California 90255, United States
  • Paradigm Clinical Research Centers- Site Number : 8400059
    La Mesa, California 91942, United States
  • Matrix Clinical Research - Los Angeles- Site Number : 8400008
    Los Angeles, California 90057, United States
  • Kaiser Permanente - Oakland Medical Center- Site Number : 8400047
    Oakland, California 94611, United States
  • Stanford University Medical Center CTRU - 800 Welch Road- Site Number : 8400070
    Palo Alto, California 94304, United States
  • Kaiser Permanente - Sierra Gardens- Site Number : 8400063
    Roseville, California 95661, United States
  • Kaiser Permanente - Point West Medical Offices- Site Number : 8400064
    Sacramento, California 95815, United States
  • Kaiser Permanente - San Jose Medical Center- Site Number : 8400060
    San Jose, California 95119, United States
  • Kaiser Permanente - Santa Clara Medical Center- Site Number : 8400061
    Santa Clara, California 95051, United States
  • Integrated Clinical Research LLC- Site Number : 8400036
    Sherman Oaks, California 91356-4173, United States
  • Kaiser Permanente - Walnut Creek Medical Center- Site Number : 8400062
    Walnut Creek, California 94596, United States
  • Velocity Clinical Research - Washington DC- Site Number : 8400050
    Washington D.C., District of Columbia 20016, United States
  • Prohealth Research Center- Site Number : 8400068
    Doral, Florida 33166, United States
  • The Medici Medical Research- Site Number : 8400055
    Hollywood, Florida 33021, United States
  • Dade Research Center- Site Number : 8400014
    Miami, Florida 33126, United States
  • Riveldi Biomedical Research and Associates - Miami Lakes- Site Number : 8400015
    Miami Lakes, Florida 33014, United States
  • SEC Clinical Research - Pensacola- Site Number : 8400034
    Pensacola, Florida 32501, United States
  • PAS Research- Site Number : 8400005
    Tampa, Florida 33613, United States
  • Leavitt Women's Healthcare- Site Number : 8400009
    Idaho Falls, Idaho 83404, United States
  • Velocity Clinical Research - Sioux City- Site Number : 8400054
    Sioux City, Iowa 51106, United States
  • Alliance for Multispeciality Research - El Dorado- Site Number : 8400019
    El Dorado, Kansas 67042, United States
  • University of Kentucky Chandler Medical Center- Site Number : 8400051
    Lexington, Kentucky 40536, United States
  • Velocity Clinical Research - New Orleans- Site Number : 8400058
    New Orleans, Louisiana 70119, United States
  • Research Works INC- Site Number : 8400044
    New Orleans, Louisiana 70125, United States
  • Velocity Clinical Research - Gulfport- Site Number : 8400011
    Gulfport, Mississippi 39503, United States
  • QPS Bio-Kinetic Clinical Applications- Site Number : 8400046
    Springfield, Missouri 65802, United States
  • Boeson Research - Great Falls- Site Number : 8400041
    Great Falls, Montana 59405, United States
  • Boeson Research - Missoula- Site Number : 8400006
    Missoula, Montana 59804, United States
  • Velocity Clinical Research - Grand Island- Site Number : 8400016
    Grand Island, Nebraska 68803, United States
  • Midwest Childrens Health Research Institute- Site Number : 8400038
    Lincoln, Nebraska 68516, United States
  • Velocity Clinical Research - Omaha- Site Number : 8400001
    Omaha, Nebraska 68134, United States
  • PAS Research - Henderson- Site Number : 8400049
    Henderson, Nevada 89014, United States
  • NYU Langone Cardiothoracic Surgery Associates - Garden City- Site Number : 8400048
    Garden City, New York 11530, United States
  • Summerwood Pediatrics- Site Number : 8400021
    Liverpool, New York 13088, United States
  • SUNY Upstate Medical University - Syracuse- Site Number : 8400029
    Syracuse, New York 13210, United States
  • Dayton Clinical Research- Site Number : 8400030
    Dayton, Ohio 45409, United States
  • Ohio Pediatrics - Dayton- Site Number : 8400033
    Dayton, Ohio 45414, United States
  • Senders Pediatrics- Site Number : 8400022
    South Euclid, Ohio 44121, United States
  • Cyn3rgy Research- Site Number : 8400053
    Gresham, Oregon 97030, United States
  • Square-1 Clinical Research- Site Number : 8400031
    Erie, Pennsylvania 16506, United States
  • Pas Research - Pittsburgh- Site Number : 8400043
    Pittsburgh, Pennsylvania 15227, United States
  • Neighbors Pediatrics- Site Number : 8400072
    Charleston, South Carolina 29407, United States
  • Tribe Clinical Research - Greenville - Verdae Boulevard- Site Number : 8400012
    Greenville, South Carolina 29607, United States
  • South Texas Clinical Research- Site Number : 8400004
    Corpus Christi, Texas 78413, United States
  • Javara - Privia Medical Group North Texas - Dallas- Site Number : 8400003
    Dallas, Texas 75230, United States
  • PAS Research - Children's Care Clinic- Site Number : 8400035
    Edinburg, Texas 78539, United States
  • Helios Clinical Research - Fort Worth - 8th Avenue- Site Number : 8400020
    Fort Worth, Texas 76104, United States
  • Ventavia Research Group - Houston - North Loop West- Site Number : 8400010
    Houston, Texas 77008, United States
  • The University of Texas Health Science Center- Site Number : 8400037
    Houston, Texas 77030, United States
  • DM Clinical Research - Houston - Jones Road- Site Number : 8400052
    Houston, Texas 77065, United States
  • Mercury Clinical Research - Houston - Savoy Drive- Site Number : 8400045
    Houston, Texas 77070, United States
  • La Providence Pediatrics & Family Clinics- Site Number : 8400039
    Houston, Texas 77071, United States
  • Houston Clinical Research Associates- Site Number : 8400013
    Houston, Texas 77090, United States
  • University of Texas Medical Branch at Galveston- Site Number : 8400057
    League City, Texas 77555, United States
  • Maximos Ob/Gyn- Site Number : 8400024
    League City, Texas 77573, United States
  • Research Your Health- Site Number : 8400066
    Plano, Texas 75093, United States
  • Pediatric Center - Richmond- Site Number : 8400032
    Richmond, Texas 77469, United States
  • North Houston Internal Medicine & Pediatric Clinic- Site Number : 8400025
    Tomball, Texas 77375, United States
  • Utah Valley Pediatrics - Orem- Site Number : 8400067
    Orem, Utah 84057, United States
  • Ogden Clinic - Mountain View - CCT Research- Site Number : 8400056
    Pleasant View, Utah 84404, United States
  • Wee Care Pediatrics - Roy- Site Number : 8400071
    Roy, Utah 84067, United States
  • Investigational Site Number : 4840001
    Mexico City, Mexico City 04530, Mexico
  • Investigational Site Number : 4840002
    Temixco, Morelos 62587, Mexico
  • Investigational Site Number : 4840004
    Mexico City, 06760, Mexico
  • Investigational Site Number : 6300001
    Caguas, 00725, Puerto Rico
  • Investigational Site Number : 6300003
    Ponce, 00716, Puerto Rico
  • Investigational Site Number : 6300004
    Trujillo Alto, 00976, Puerto Rico
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Sep 2025, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2024
First posted
May 3, 2024
StartActual
May 13, 2024
Primary completionActual
Sep 18, 2025
CompletionActual
Sep 18, 2025
Results delay requested
Sep 15, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, registry dates and site details
1 update, last Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Minor edits only
    + 3 other changes: verification date, registry dates and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06397768
Responsible party
Sponsor
First posted
May 3, 2024
Start date
May 13, 2024
Primary completion
Sep 18, 2025
Completion
Sep 18, 2025
Last update
Oct 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vaxelis · Pentacel · Measles-Mumps-Rubella Vaccine · Chickenpox Vaccine

Start the discussion